|08/31/16||Coherus BioSciences Announces New Employment Inducement Grants|
|REDWOOD CITY, Calif., Aug. 31, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that effective August 31, 2016, the compensation committee of the company’s board of directors granted 6 new employees options to purchase an aggregate of 80,000 shares of the company’s common stock with a per share exercise price of $29.77, the closing trading price on the grant date. The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commence... |
|08/09/16||Coherus BioSciences Reports Second Quarter 2016 Financial and Operating Results|
|Continued execution on multiple fronts positions the company strongly for the second-half of 2016 and beyond
REDWOOD CITY, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today reported financial results and reviewed corporate events for the second quarter ended June 30, 2016.
Corporate Highlights for the Second Quarter 2016 Include:
Immunology (anti-TNF) therapeutic franchise:
CHS-1420 (adalimumab (HUMIRA®) biosimilar)
Received f... |
|08/09/16||Coherus BioSciences Submits 351(k) Biologics License Application to U.S. Food and Drug Administration for CHS-1701 (Pegfilgrastim Biosimilar Candidate)|
|REDWOOD CITY, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today announced submission of the biologics license application (BLA) for CHS-1701, a pegfilgrastim (Neulasta®) biosimilar candidate, to U.S. FDA under the 351(k) pathway.
The BLA submission is supported by similarity data from analytical, pharmacokinetic, pharmacodynamic and immunogenicity studies comparing CHS-1701 and Neulasta.
“The CHS-1701 BLA submission marks a significant milestone ... |
|08/08/16||Coherus BioSciences Announces Positive Topline Phase Three Results for CHS-1420 (Humira® Biosimilar Candidate) in Patients with Psoriasis|
|REDWOOD CITY, Calif., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today reported topline results from an ongoing Phase 3 clinical study of CHS-1420, an adalimumab (Humira®) biosimilar candidate. This study met its primary endpoint demonstrating similarity between CHS-1420 and Humira with respect to percentage of subjects achieving 75% improvement in psoriasis area and severity index (PASI-75) at Week 12. The 95% confidence intervals for the difference betwe... |